These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 3707669)

  • 21. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spironolactone. II. Bioavailability.
    Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
    Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Biological availability of spironolactone in two different galenic forms (author's transl)].
    Rameis H; Hitzenberger G; Horwatitsch H
    Dtsch Med Wochenschr; 1979 Jun; 104(24):881-3. PubMed ID: 446311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spironolactone metabolism in man studied by gas chromatography-mass spectrometry.
    Karim A; Hribar J; Aksamit W; Doherty M; Chinn LJ
    Drug Metab Dispos; 1975; 3(6):467-78. PubMed ID: 1221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.
    Gardiner P; Schrode K; Quinlan D; Martin BK; Boreham DR; Rogers MS; Stubbs K; Smith M; Karim A
    J Clin Pharmacol; 1989 Apr; 29(4):342-7. PubMed ID: 2723123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New insights into the pharmacokinetics of spironolactone.
    Overdiek HW; Hermens WA; Merkus FW
    Clin Pharmacol Ther; 1985 Oct; 38(4):469-74. PubMed ID: 4042530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of spironolactone metabolites in plasma and target organs of guinea pigs.
    Los LE; Coddington AB; Ramjit HG; Colby HD
    Drug Metab Dispos; 1993; 21(6):1086-90. PubMed ID: 7905388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacokinetics and bioequivalence of various oral formulations of metoclopramide].
    Vergin H; Bishop-Freudling GB; Strobel K; Reeves DS
    Arzneimittelforschung; 1983; 33(3):458-62. PubMed ID: 6683523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canrenone--the principal active metabolite of spironolactone?
    Ramsay LE; Shelton JR; Wilkinson D; Tidd MJ
    Br J Clin Pharmacol; 1976 Aug; 3(4):607-12. PubMed ID: 22216502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progestogens with antimineralocorticoid activity.
    Losert W; Casals-Stenzel J; Buse M
    Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.
    Krause W; Karras J; Seifert W
    Eur J Clin Pharmacol; 1983; 25(4):449-53. PubMed ID: 6653638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone.
    Platt D; Abshagen U; Mühlberg W; Horn HJ; Schmitt-Rüth R; Vollmar J
    Arch Gerontol Geriatr; 1984 Jul; 3(2):147-59. PubMed ID: 6476975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldosterone antagonism studies in the rhesus monkey.
    Hofmann LM; Pedrera HA; Suleymamov OD
    J Pharmacol Exp Ther; 1977 Jul; 202(1):216-20. PubMed ID: 406381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Skin blister fluid--an access to the peripheral compartment. Implications of a study on the behaviour of bendroflumethiazide in rats.
    Schäfer-Korting M
    Arzneimittelforschung; 1985; 35(12):1828-31. PubMed ID: 4096738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.
    Mück W; Ritter W; Ochmann K; Unger S; Ahr G; Wingender W; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):255-60. PubMed ID: 9208342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose administration.
    Martins ML; Pierossi MA; Moraes LA; Ribeiro W; Abbib Júnior E; Mendes GB; Poli A; De Nucci G; Muscará MN
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):324-8. PubMed ID: 9266287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
    Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
    Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative bioavailability of two forms of spironolactone. Rationalization applied to dosage (author's transl)].
    d'Athis P; Richard MO; de Lauture D; Rey E; Bouvier d'Yvoire M; Clement E; Olive G
    Therapie; 1981; 36(4):443-9. PubMed ID: 7292427
    [No Abstract]   [Full Text] [Related]  

  • 39. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
    Krause W; Karras J; Jakobs U
    J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs.
    Jeunesse E; Woehrle F; Schneider M; Lefebvre HP
    J Vet Cardiol; 2007 Nov; 9(2):63-8. PubMed ID: 18024236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.